Beta-glucan-chitin-chitosan Polymer Supplement in Overweight/Obese Subjects: Cardiovascular Risk Biomarkers (QUITOVASC)

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

October 24, 2017

Study Completion Date

October 24, 2017

Conditions
Dietary Exposure
Interventions
DIETARY_SUPPLEMENT

βGluCnCs intervention

"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."

DIETARY_SUPPLEMENT

Placebo intervention

"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."

Trial Locations (1)

08025

Institut Recerca-Hospital Santa Creu I Sant Pau, Barcelona

All Listed Sponsors
lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT06622447 - Beta-glucan-chitin-chitosan Polymer Supplement in Overweight/Obese Subjects: Cardiovascular Risk Biomarkers (QUITOVASC) | Biotech Hunter | Biotech Hunter